GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » ROE %

BSGM (BioSig Technologies) ROE % : -1,769.94% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioSig Technologies's annualized net income for the quarter that ended in Mar. 2025 was $-11.25 Mil. BioSig Technologies's average Total Stockholders Equity over the quarter that ended in Mar. 2025 was $0.64 Mil. Therefore, BioSig Technologies's annualized ROE % for the quarter that ended in Mar. 2025 was -1,769.94%.

The historical rank and industry rank for BioSig Technologies's ROE % or its related term are showing as below:

BSGM's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.38
* Ranked among companies with meaningful ROE % only.

BioSig Technologies ROE % Historical Data

The historical data trend for BioSig Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies ROE % Chart

BioSig Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -291.43 -173.36 -423.88 - -

BioSig Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -1,769.94

Competitive Comparison of BioSig Technologies's ROE %

For the Medical Devices subindustry, BioSig Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's ROE % falls into.


;
;

BioSig Technologies ROE % Calculation

BioSig Technologies's annualized ROE % for the fiscal year that ended in Dec. 2024 is calculated as

ROE %=Net Income (A: Dec. 2024 )/( (Total Stockholders Equity (A: Dec. 2023 )+Total Stockholders Equity (A: Dec. 2024 ))/ count )
=-10.33/( (-2.913+-1.439)/ 2 )
=-10.33/-2.176
=N/A %

BioSig Technologies's annualized ROE % for the quarter that ended in Mar. 2025 is calculated as

ROE %=Net Income (Q: Mar. 2025 )/( (Total Stockholders Equity (Q: Dec. 2024 )+Total Stockholders Equity (Q: Mar. 2025 ))/ count )
=-11.248/( (-1.439+2.71)/ 2 )
=-11.248/0.6355
=-1,769.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. ROE % is displayed in the 30-year financial page.


BioSig Technologies  (NAS:BSGM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-11.248/0.6355
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-11.248 / 0)*(0 / 2.63)*(2.63 / 0.6355)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*4.1385
=ROA %*Equity Multiplier
=N/A %*4.1385
=-1,769.94 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-11.248/0.6355
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-11.248 / -11.2) * (-11.2 / -11.936) * (-11.936 / 0) * (0 / 2.63) * (2.63 / 0.6355)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0043 * 0.9383 * N/A % * 0 * 4.1385
=-1,769.94 %

Note: The net income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


BioSig Technologies ROE % Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies Business Description

Traded in Other Exchanges
N/A
Address
12424 Wilshire Boulevard, Suite 745, Los Angeles, CA, USA, 90025
BioSig Technologies Inc is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP Platform enables electrophysiologists to acquire raw signal data in real-time, absent unnecessary noise or interference, to maximize procedural success and minimize unnecessary inefficiencies.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044

BioSig Technologies Headlines

From GuruFocus